JP2013010792A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013010792A5 JP2013010792A5 JP2012226367A JP2012226367A JP2013010792A5 JP 2013010792 A5 JP2013010792 A5 JP 2013010792A5 JP 2012226367 A JP2012226367 A JP 2012226367A JP 2012226367 A JP2012226367 A JP 2012226367A JP 2013010792 A5 JP2013010792 A5 JP 2013010792A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- compound according
- hydrogen
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 42
- 239000000203 mixture Substances 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims 38
- 229910052739 hydrogen Inorganic materials 0.000 claims 25
- 239000001257 hydrogen Substances 0.000 claims 25
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 20
- 229910052731 fluorine Inorganic materials 0.000 claims 9
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 claims 8
- 125000001931 aliphatic group Chemical group 0.000 claims 8
- 239000011737 fluorine Substances 0.000 claims 8
- 229910052799 carbon Inorganic materials 0.000 claims 7
- 239000003814 drug Substances 0.000 claims 7
- 229940079593 drug Drugs 0.000 claims 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 5
- 229910052736 halogen Inorganic materials 0.000 claims 5
- 150000002367 halogens Chemical class 0.000 claims 5
- 150000002431 hydrogen Chemical class 0.000 claims 5
- 125000000217 alkyl group Chemical group 0.000 claims 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 3
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 3
- -1 COOR' Chemical group 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 239000012472 biological sample Substances 0.000 claims 2
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 208000020084 Bone disease Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 208000029462 Immunodeficiency disease Diseases 0.000 claims 1
- 108010025020 Nerve Growth Factor Proteins 0.000 claims 1
- 102000007072 Nerve Growth Factors Human genes 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 125000002723 alicyclic group Chemical group 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 230000001028 anti-proliverative effect Effects 0.000 claims 1
- 239000003443 antiviral agent Substances 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 125000002837 carbocyclic group Chemical group 0.000 claims 1
- 150000001721 carbon Chemical group 0.000 claims 1
- 230000000973 chemotherapeutic effect Effects 0.000 claims 1
- 230000001066 destructive effect Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000014951 hematologic disease Diseases 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 229940121354 immunomodulator Drugs 0.000 claims 1
- 230000002584 immunomodulator Effects 0.000 claims 1
- 229960003444 immunosuppressant agent Drugs 0.000 claims 1
- 230000001861 immunosuppressant effect Effects 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 208000019423 liver disease Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000003900 neurotrophic factor Substances 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 0 Cc1cnc2[n]cc(C(N=C(*)*)=NC(*)=I)c2c1 Chemical compound Cc1cnc2[n]cc(C(N=C(*)*)=NC(*)=I)c2c1 0.000 description 20
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- PSDSIQPUXJCFBK-UHFFFAOYSA-N C(C1C2)C3C11C4C2C3CC1C4 Chemical compound C(C1C2)C3C11C4C2C3CC1C4 PSDSIQPUXJCFBK-UHFFFAOYSA-N 0.000 description 1
- VVRCYUOEOIOIEK-UHFFFAOYSA-O CC(C(N(C)CC(F)(F)F)=O)Nc1nc(C2=C[NH2+]c3ncccc23)ncc1 Chemical compound CC(C(N(C)CC(F)(F)F)=O)Nc1nc(C2=C[NH2+]c3ncccc23)ncc1 VVRCYUOEOIOIEK-UHFFFAOYSA-O 0.000 description 1
- DZDNCAJEJCQSMR-UHFFFAOYSA-N CC(C)(C)C1N(C)CSC1 Chemical compound CC(C)(C)C1N(C)CSC1 DZDNCAJEJCQSMR-UHFFFAOYSA-N 0.000 description 1
- GDHIUXDCYFUUAE-INIZCTEOSA-N CC(C)[C@@H](NCOCNCC(F)(F)F)Nc1ccnc(-c2c[nH]c3ncccc23)n1 Chemical compound CC(C)[C@@H](NCOCNCC(F)(F)F)Nc1ccnc(-c2c[nH]c3ncccc23)n1 GDHIUXDCYFUUAE-INIZCTEOSA-N 0.000 description 1
- QOVARRUAEFTPOJ-UHFFFAOYSA-O CC(CC1C([NH2+]CC(F)(F)F)=O)(CN1c1nc(-c2c[nH]c3ncccc23)ncc1)F Chemical compound CC(CC1C([NH2+]CC(F)(F)F)=O)(CN1c1nc(-c2c[nH]c3ncccc23)ncc1)F QOVARRUAEFTPOJ-UHFFFAOYSA-O 0.000 description 1
- RJCGAHHUKISJIM-UHFFFAOYSA-N CC(CCC1)(C(NCC(CCF)F)=O)N1c1ccnc(-c2c[nH]c3ncccc23)n1 Chemical compound CC(CCC1)(C(NCC(CCF)F)=O)N1c1ccnc(-c2c[nH]c3ncccc23)n1 RJCGAHHUKISJIM-UHFFFAOYSA-N 0.000 description 1
- GGFKQOQFSGPWBG-UHFFFAOYSA-N CC(NCC(F)(F)F)=O Chemical compound CC(NCC(F)(F)F)=O GGFKQOQFSGPWBG-UHFFFAOYSA-N 0.000 description 1
- MKPZDBNKUJHYCK-UHFFFAOYSA-N CC1N(C)CC1 Chemical compound CC1N(C)CC1 MKPZDBNKUJHYCK-UHFFFAOYSA-N 0.000 description 1
- HPFBCTLYLKRWHC-LJQANCHMSA-N CCCN(C[C@H](C(NCC(F)(F)[F]C)=O)Nc1ccnc(-c2c[nH]c3ncccc23)n1)C(C=C(C)C)=O Chemical compound CCCN(C[C@H](C(NCC(F)(F)[F]C)=O)Nc1ccnc(-c2c[nH]c3ncccc23)n1)C(C=C(C)C)=O HPFBCTLYLKRWHC-LJQANCHMSA-N 0.000 description 1
- RAZUSFPITOYAFO-UHFFFAOYSA-N CCN(CCCCC(NCC(F)(F)F)=O)c1nc(-c2cnc3ncccc23)ncc1F Chemical compound CCN(CCCCC(NCC(F)(F)F)=O)c1nc(-c2cnc3ncccc23)ncc1F RAZUSFPITOYAFO-UHFFFAOYSA-N 0.000 description 1
- CQUBJFQPRYBVRL-MRVPVSSYSA-N C[C@H](C(NCC(F)(F)F)=O)Nc1nc(-c2c[nH]c3ncccc23)ncn1 Chemical compound C[C@H](C(NCC(F)(F)F)=O)Nc1nc(-c2c[nH]c3ncccc23)ncn1 CQUBJFQPRYBVRL-MRVPVSSYSA-N 0.000 description 1
- TYGGIVKWEZXSEO-UHFFFAOYSA-O FC(C[NH2+]CC(CSC1)N1c1nc(-c2c[nH]c3ncccc23)ncc1)(F)F Chemical compound FC(C[NH2+]CC(CSC1)N1c1nc(-c2c[nH]c3ncccc23)ncc1)(F)F TYGGIVKWEZXSEO-UHFFFAOYSA-O 0.000 description 1
- KYSLPFWJGHXTEG-UHFFFAOYSA-O Fc1cnc(C2=C[NH2+]c3ncccc23)nc1N1CCNCC1 Chemical compound Fc1cnc(C2=C[NH2+]c3ncccc23)nc1N1CCNCC1 KYSLPFWJGHXTEG-UHFFFAOYSA-O 0.000 description 1
- DKMRYSYNTIZLMX-UHFFFAOYSA-P NC(CC(C1)F)(C([NH2+]CC(F)(F)F)=O)N1c1nc(C2=C[NH2+]c3c2cccn3)ncc1 Chemical compound NC(CC(C1)F)(C([NH2+]CC(F)(F)F)=O)N1c1nc(C2=C[NH2+]c3c2cccn3)ncc1 DKMRYSYNTIZLMX-UHFFFAOYSA-P 0.000 description 1
- PGHMUTCFECJKIO-UHFFFAOYSA-P O=C(C(CSC1)N1c1nc(C2=C[NH2+]c3c2cccn3)ncc1)[NH2+]CC(F)(F)F Chemical compound O=C(C(CSC1)N1c1nc(C2=C[NH2+]c3c2cccn3)ncc1)[NH2+]CC(F)(F)F PGHMUTCFECJKIO-UHFFFAOYSA-P 0.000 description 1
- OLYGQFHFXLFKDY-GFCCVEGCSA-N O=C([C@@H](CC(C1)(F)F)N1c1nc(-c2c[nH]c3ncccc23)ncc1F)NCC(F)(F)F Chemical compound O=C([C@@H](CC(C1)(F)F)N1c1nc(-c2c[nH]c3ncccc23)ncc1F)NCC(F)(F)F OLYGQFHFXLFKDY-GFCCVEGCSA-N 0.000 description 1
- CZCYCVDAGWFZSN-TVQRCGJNSA-N O[C@@H](C[C@@H]1C(NCC(F)(F)F)=O)CN1c1nc(-c2c[nH]c3ncccc23)ncc1F Chemical compound O[C@@H](C[C@@H]1C(NCC(F)(F)F)=O)CN1c1nc(-c2c[nH]c3ncccc23)ncc1F CZCYCVDAGWFZSN-TVQRCGJNSA-N 0.000 description 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US75936706P | 2006-01-17 | 2006-01-17 | |
| US60/759,367 | 2006-01-17 | ||
| US84247106P | 2006-09-06 | 2006-09-06 | |
| US60/842,471 | 2006-09-06 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008551353A Division JP5591471B2 (ja) | 2006-01-17 | 2007-01-17 | ヤヌスキナーゼ阻害剤として有用なアザインドール |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014167160A Division JP2014210823A (ja) | 2006-01-17 | 2014-08-20 | ヤヌスキナーゼ阻害剤として有用なアザインドール |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013010792A JP2013010792A (ja) | 2013-01-17 |
| JP2013010792A5 true JP2013010792A5 (enExample) | 2014-10-02 |
| JP5728454B2 JP5728454B2 (ja) | 2015-06-03 |
Family
ID=38197739
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008551353A Expired - Fee Related JP5591471B2 (ja) | 2006-01-17 | 2007-01-17 | ヤヌスキナーゼ阻害剤として有用なアザインドール |
| JP2012226367A Expired - Fee Related JP5728454B2 (ja) | 2006-01-17 | 2012-10-11 | ヤヌスキナーゼ阻害剤として有用なアザインドール |
| JP2012226368A Ceased JP2013010793A (ja) | 2006-01-17 | 2012-10-11 | ヤヌスキナーゼ阻害剤として有用なアザインドール |
| JP2014167160A Pending JP2014210823A (ja) | 2006-01-17 | 2014-08-20 | ヤヌスキナーゼ阻害剤として有用なアザインドール |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008551353A Expired - Fee Related JP5591471B2 (ja) | 2006-01-17 | 2007-01-17 | ヤヌスキナーゼ阻害剤として有用なアザインドール |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012226368A Ceased JP2013010793A (ja) | 2006-01-17 | 2012-10-11 | ヤヌスキナーゼ阻害剤として有用なアザインドール |
| JP2014167160A Pending JP2014210823A (ja) | 2006-01-17 | 2014-08-20 | ヤヌスキナーゼ阻害剤として有用なアザインドール |
Country Status (19)
| Country | Link |
|---|---|
| US (6) | US7767816B2 (enExample) |
| EP (3) | EP1973911B1 (enExample) |
| JP (4) | JP5591471B2 (enExample) |
| KR (3) | KR101235103B1 (enExample) |
| CN (3) | CN102532133A (enExample) |
| AR (1) | AR060316A1 (enExample) |
| AU (1) | AU2007207533B8 (enExample) |
| BR (2) | BRPI0722364A2 (enExample) |
| CA (1) | CA2636189A1 (enExample) |
| CL (1) | CL2008002140A1 (enExample) |
| HK (1) | HK1210780A1 (enExample) |
| IL (1) | IL191902A0 (enExample) |
| NO (1) | NO20083501L (enExample) |
| NZ (3) | NZ592968A (enExample) |
| RU (2) | RU2453548C2 (enExample) |
| TW (4) | TW201412738A (enExample) |
| UA (1) | UA95940C2 (enExample) |
| WO (1) | WO2007084557A2 (enExample) |
| ZA (2) | ZA200805053B (enExample) |
Families Citing this family (102)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7507826B2 (en) | 2004-03-30 | 2009-03-24 | Vertex Pharmaceuticals Incorporated | Azaindoles useful as inhibitors of JAK and other protein kinases |
| KR20080016659A (ko) * | 2005-05-20 | 2008-02-21 | 버텍스 파마슈티칼스 인코포레이티드 | 단백질 키나제의 억제제로서 유용한 피롤로피리딘 |
| EP2270014A1 (en) | 2005-09-22 | 2011-01-05 | Incyte Corporation | Azepine inhibitors of janus kinases |
| CN103214484B (zh) | 2005-12-13 | 2016-07-06 | 因塞特控股公司 | 作为两面神激酶抑制剂的杂芳基取代的吡咯并[2,3-b]吡啶和吡咯并[2,3-b]嘧啶 |
| TW201412738A (zh) | 2006-01-17 | 2014-04-01 | Vertex Pharma | 適合作為傑納斯激酶（ｊａｎｕｓ ｋｉｎａｓｅ）抑制劑之氮雜吲哚 |
| CA2648250A1 (en) * | 2006-04-05 | 2007-10-18 | Vertex Pharmaceuticals Incorporated | Deazapurines useful as inhibitors of janus kinases |
| US7754838B2 (en) * | 2006-08-08 | 2010-07-13 | E.I. Du Pont De Nemours And Company | Poly(meth)acrylamides and poly(meth)acrylates containing fluorinated amide |
| NZ577798A (en) | 2006-12-21 | 2012-04-27 | Vertex Pharma | 5-cyano-4- (pyrrolo [2, 3b] pyridine-3-yl) -pyrimidine derivatives useful as protein kinase inhibitors |
| ES2415863T3 (es) | 2006-12-22 | 2013-07-29 | Incyte Corporation | Heterociclos sustituidos como inhibidores de Janus Quinasas |
| JP5642973B2 (ja) * | 2007-03-22 | 2014-12-17 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | Ｊａｋ阻害薬として有用なｎ−複素環式化合物 |
| CL2008001709A1 (es) | 2007-06-13 | 2008-11-03 | Incyte Corp | Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras. |
| HUE029236T2 (en) | 2007-06-13 | 2017-02-28 | Incyte Holdings Corp | (R) -3- (4- (7H-Pyrrolo [2,3-d] pyrimidin-4-yl) -1H-pyrazol-1-yl) -3-cyclopentylpropanenitrile Crystalline salts of Janus kinase inhibitor |
| JP2011513483A (ja) * | 2008-03-10 | 2011-04-28 | バーテックス ファーマシューティカルズ インコーポレイテッド | タンパク質キナーゼの阻害剤として有用なピリミジンおよびピリジン |
| TWI444382B (zh) | 2008-03-11 | 2014-07-11 | Incyte Corp | 作為ｊａｋ抑制劑之氮雜環丁烷及環丁烷衍生物 |
| AU2009274011B2 (en) * | 2008-07-23 | 2014-12-18 | Vertex Pharmaceuticals Incorporated | Pyrazolopyridine kinase inhibitors |
| EP2432472B1 (en) | 2009-05-22 | 2019-10-02 | Incyte Holdings Corporation | 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors |
| MY156727A (en) | 2009-05-22 | 2016-03-15 | Incyte Corp | N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
| DK2442809T3 (en) * | 2009-06-17 | 2016-12-19 | Vertex Pharma | Inhibitors of the replication of influenza virus |
| TW201113285A (en) | 2009-09-01 | 2011-04-16 | Incyte Corp | Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
| MX2012004180A (es) | 2009-10-09 | 2012-07-17 | Incyte Corp | Derivados de hidroxil, ceto y glucuronido de 3-(4-7h-pirrolo[2,3-d ]pirimidin-a-il)-1h-pirazol-1-il)-3-ciclopentilpropanonitrilo. |
| DK2516434T3 (en) | 2009-12-23 | 2015-08-31 | Takeda Pharmaceutical | FUSED HETEROAROMATIC PYRROLIDINONS AS SICK INHIBITORS |
| EP3354652B1 (en) | 2010-03-10 | 2020-05-06 | Incyte Holdings Corporation | Piperidin-4-yl azetidine derivatives as jak1 inhibitors |
| US8481541B2 (en) | 2010-03-22 | 2013-07-09 | Hoffmann-La Roche Inc. | Pyrrolopyrazine kinase inhibitors |
| WO2011137022A1 (en) * | 2010-04-27 | 2011-11-03 | Merck Sharp & Dohme Corp. | Azaindoles as janus kinase inhibitors |
| RU2012152354A (ru) | 2010-05-20 | 2014-06-27 | Ф. Хоффманн-Ля Рош Аг | Производные пирролопиразина в качестве ингибиторов syk и jak |
| AR084691A1 (es) | 2010-05-21 | 2013-06-05 | Incyte Corp | Formulacion de uso topico para un inhibidor de jak y metodo para tratar trastorno de la piel |
| US9198911B2 (en) | 2010-11-02 | 2015-12-01 | The Trustees Of Columbia University In The City Of New York | Methods for treating hair loss disorders |
| WO2012068440A1 (en) | 2010-11-19 | 2012-05-24 | Incyte Corporation | Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors |
| CA2818542A1 (en) | 2010-11-19 | 2012-05-24 | Incyte Corporation | Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors |
| CN103492382A (zh) | 2010-12-16 | 2014-01-01 | 沃泰克斯药物股份有限公司 | 流感病毒复制的抑制剂 |
| KR20130128435A (ko) | 2010-12-16 | 2013-11-26 | 버텍스 파마슈티칼스 인코포레이티드 | 인플루엔자 바이러스 복제의 억제제 |
| AU2011343642A1 (en) | 2010-12-16 | 2013-05-02 | Vertex Pharmaceuticals Incorporated | Inhibitors of influenza viruses replication |
| DE102011009961A1 (de) * | 2011-02-01 | 2012-08-02 | Merck Patent Gmbh | 7-Azaindolderivate |
| WO2012112847A1 (en) | 2011-02-18 | 2012-08-23 | Novartis Pharma Ag | mTOR/JAK INHIBITOR COMBINATION THERAPY |
| CN103547580B (zh) | 2011-03-22 | 2016-12-07 | 阿迪维纳斯疗法有限公司 | 取代的稠合三环化合物、其组合物及医药用途 |
| WO2012160464A1 (en) | 2011-05-26 | 2012-11-29 | Daiichi Sankyo Company, Limited | Heterocyclic compounds as protein kinase inhibitors |
| MY165963A (en) | 2011-06-20 | 2018-05-18 | Incyte Holdings Corp | Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors |
| WO2012177714A1 (en) | 2011-06-22 | 2012-12-27 | Takeda Pharmaceutical Company Limited | Substituted 6-aza-isoindolin-1-one derivatives |
| NZ714502A (en) * | 2011-07-05 | 2017-04-28 | Vertex Pharma | Processes and intermediates for producing azaindoles |
| UA118010C2 (uk) | 2011-08-01 | 2018-11-12 | Вертекс Фармасьютікалз Інкорпорейтед | Інгібітори реплікації вірусів грипу |
| CA2844507A1 (en) | 2011-08-10 | 2013-02-14 | Novartis Pharma Ag | Jak pi3k/mtor combination therapy |
| TW201313721A (zh) | 2011-08-18 | 2013-04-01 | Incyte Corp | 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物 |
| UA111854C2 (uk) | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | Способи і проміжні сполуки для отримання інгібіторів jak |
| MX2014005565A (es) | 2011-11-07 | 2014-05-30 | Vertex Pharma | Metodos para tratar enfermedades inflamatorias y composiciones farmaceuticas utiles para los mismos. |
| CA3131037A1 (en) | 2011-11-30 | 2013-06-06 | Emory University | Antiviral jak inhibitors useful in treating or preventing retroviral and other viral infections |
| UY34615A (es) * | 2012-02-10 | 2013-09-30 | Galapagos Nv | Nuevos compuestos útiles para el tratamiento de enfermedades degenerativas e inflamatorias. |
| WO2013117649A1 (en) * | 2012-02-10 | 2013-08-15 | Galapagos Nv | Imidazo [4, 5 -c] pyridine derivatives useful for the treatment of degenerative and inflammatory diseases |
| ES2694681T3 (es) * | 2012-03-29 | 2018-12-26 | The Trustees Of Columbia University In The City Of New York | Métodos para tratar trastornos de pérdida capilar |
| WO2013173506A2 (en) | 2012-05-16 | 2013-11-21 | Rigel Pharmaceuticals, Inc. | Method of treating muscular degradation |
| TW201406761A (zh) | 2012-05-18 | 2014-02-16 | Incyte Corp | 做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物 |
| WO2013184985A1 (en) | 2012-06-08 | 2013-12-12 | Vertex Pharmaceuticals Incorporated | Inhibitors of influenza viruses replication |
| WO2014013014A1 (en) | 2012-07-18 | 2014-01-23 | Fundació Privada Centre De Regulació Genòmica (Crg) | Jak inhibitors for activation of epidermal stem cell populations |
| IN2015DN02008A (enExample) | 2012-09-21 | 2015-08-14 | Advinus Therapeutics Ltd | |
| WO2014074471A1 (en) | 2012-11-06 | 2014-05-15 | Vertex Pharmaceuticals Incorporated | Methods for treating inflammatory diseases and pharmaceutical combinations useful therefor |
| TWI761825B (zh) | 2012-11-15 | 2022-04-21 | 美商英塞特控股公司 | 盧梭利替尼之緩釋性劑型 |
| WO2014089280A1 (en) * | 2012-12-07 | 2014-06-12 | Calitor Sciences, Llc | Alkynyl compounds and methods of use |
| WO2014110259A1 (en) | 2013-01-09 | 2014-07-17 | Vertex Pharmaceuticals Incorporated | Solid forms of a jak inhibitor |
| EP2945623B1 (en) * | 2013-01-15 | 2018-09-05 | Suzhou Kintor Pharmaceuticals, Inc. | Hedgehog pathway signaling inhibitors and therapeutic applications thereof |
| TW201513861A (zh) * | 2013-01-17 | 2015-04-16 | Galapagos Nv | 用於治療退化性及發炎疾病之新穎化合物 |
| TWI841376B (zh) | 2013-03-01 | 2024-05-01 | 美商英塞特控股公司 | 吡唑并嘧啶衍生物治療PI3Kδ相關病症之用途 |
| MX384910B (es) | 2013-03-06 | 2025-03-14 | Incyte Holdings Corp | Procesos e intermedios para hacer un inhibidor de jak. |
| EP2976338B1 (en) * | 2013-03-19 | 2018-01-03 | Merck Sharp & Dohme Corp. | N-(2-cyano heterocyclyl)pyrazolo pyridones as janus kinase inhibitors |
| WO2014201332A1 (en) * | 2013-06-14 | 2014-12-18 | Vertex Pharmaceuticals Incorporated | Pharmaceutical combinations useful for treating rheumatoid arthritis |
| SG11201600815WA (en) | 2013-08-07 | 2016-03-30 | Incyte Corp | Sustained release dosage forms for a jak1 inhibitor |
| EP3036225A1 (en) | 2013-08-22 | 2016-06-29 | Vertex Pharmaceuticals Incorporated | Isotopically enriched azaindoles |
| US9296727B2 (en) | 2013-10-07 | 2016-03-29 | Vertex Pharmaceuticals Incorporated | Methods of regioselective synthesis of 2,4-disubstituted pyrimidines |
| EP3068776B1 (en) | 2013-11-13 | 2019-05-29 | Vertex Pharmaceuticals Incorporated | Inhibitors of influenza viruses replication |
| RS57541B1 (sr) | 2013-11-13 | 2018-10-31 | Vertex Pharma | Postupci za pripremu inhibitora replikacije virusa gripa |
| EP3070086B1 (en) | 2014-02-04 | 2018-11-21 | Taiho Pharmaceutical Co., Ltd. | Azaindole derivative |
| WO2015184305A1 (en) | 2014-05-30 | 2015-12-03 | Incyte Corporation | TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1 |
| SG11201700956VA (en) | 2014-08-08 | 2017-03-30 | Janssen Sciences Ireland Uc | Indoles for use in influenza virus infection |
| NO2721710T3 (enExample) | 2014-08-21 | 2018-03-31 | ||
| TWI679205B (zh) | 2014-09-02 | 2019-12-11 | 日商日本新藥股份有限公司 | 吡唑并噻唑化合物及醫藥 |
| EP3218485A1 (en) * | 2014-11-10 | 2017-09-20 | Glaxosmithkline Intellectual Property (No. 2) Limited | Long acting pharmaceutical compositions for hepatitis c |
| JP6460382B2 (ja) * | 2014-11-28 | 2019-01-30 | 株式会社豊田自動織機 | 飽和ヘテロ環含有化合物、並びにこれを用いた二次電池用電極及び二次電池、結着剤、蛍光物質 |
| MA42422A (fr) | 2015-05-13 | 2018-05-23 | Vertex Pharma | Inhibiteurs de la réplication des virus de la grippe |
| JP6704416B2 (ja) | 2015-05-13 | 2020-06-03 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | インフルエンザウイルスの複製の阻害剤を調製する方法 |
| TWI712604B (zh) | 2016-03-01 | 2020-12-11 | 日商日本新藥股份有限公司 | 具jak抑制作用之化合物之結晶 |
| CN109071567B (zh) * | 2016-05-19 | 2021-03-23 | 四川大学 | 抗流感小分子化合物及其制备方法和用途 |
| WO2018019223A1 (zh) * | 2016-07-26 | 2018-02-01 | 张文燕 | 作为选择性jak抑制剂化合物，该化合物的盐类及其治疗用途 |
| WO2018041989A1 (en) | 2016-09-02 | 2018-03-08 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for diagnosing and treating refractory celiac disease type 2 |
| ES2901875T3 (es) | 2017-04-24 | 2022-03-24 | Cocrystal Pharma Inc | Derivados de la pirrolopirimidina útiles como inhibidores de la replicación del virus de la influenza |
| US10596161B2 (en) | 2017-12-08 | 2020-03-24 | Incyte Corporation | Low dose combination therapy for treatment of myeloproliferative neoplasms |
| JP7393348B2 (ja) | 2018-01-30 | 2023-12-06 | インサイト・コーポレイション | （１－（３－フルオロ－２（トリフルオロメチル）イソニコチニル）ピぺリジン―４－オン）を作製するためのプロセス及び中間体 |
| US10508113B2 (en) | 2018-03-12 | 2019-12-17 | Abbvie Inc. | Inhibitors of tyrosine kinase 2 mediated signaling |
| CN113768934A (zh) | 2018-03-30 | 2021-12-10 | 因赛特公司 | 使用jak抑制剂治疗化脓性汗腺炎 |
| WO2020023813A1 (en) | 2018-07-27 | 2020-01-30 | Cocrystal Pharma, Inc. | Pyrrolo[2,3-b]pyridin derivatives as inhibitors of influenza virus replication |
| US12565488B2 (en) | 2018-11-26 | 2026-03-03 | Cocrystal Pharma, Inc. | Inhibitors of influenza virus replication |
| EP3942045A1 (en) | 2019-03-21 | 2022-01-26 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
| US20220177978A1 (en) | 2019-04-02 | 2022-06-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods of predicting and preventing cancer in patients having premalignant lesions |
| US20220202820A1 (en) | 2019-04-16 | 2022-06-30 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of jak inhibitors for the treatment of painful conditions involving nav1.7 channels |
| KR102133595B1 (ko) | 2019-05-31 | 2020-07-13 | 에이치케이이노엔 주식회사 | 단백질 키나제 억제제로서의 헤테로고리 화합물 |
| KR102112336B1 (ko) | 2019-08-12 | 2020-05-18 | 에이치케이이노엔 주식회사 | 단백질 키나제 억제제로서의 헤테로고리 화합물 |
| JP2022549506A (ja) | 2019-09-27 | 2022-11-25 | ディスク・メディシン・インコーポレイテッド | 骨髄線維症および関連状態を処置するための方法 |
| EP4054579A1 (en) | 2019-11-08 | 2022-09-14 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| US20230151034A1 (en) | 2020-03-17 | 2023-05-18 | Cocrystal Pharma, Inc. | Peptidomimetic n5-methyl-n2-(nonanoyl-l-leucyl)-l-glutaminate derivatives, triazaspiro[4.14]nonadecane derivatives and similar compounds as inhibitors of norovirus and coronavirus replication |
| KR20230012539A (ko) | 2020-05-13 | 2023-01-26 | 디스크 메디슨, 인크. | 골수섬유증을 치료하기 위한 항-헤모주벨린 (hjv) 항체 |
| US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
| EP4526469A1 (en) | 2022-05-16 | 2025-03-26 | Institut National de la Santé et de la Recherche Médicale | Methods for assessing the exhaustion of hematopoietic stems cells induced by chronic inflammation |
| KR20250170567A (ko) * | 2023-04-17 | 2025-12-05 | 아벨로스테라퓨틱스 주식회사 | 치환된 아세틸렌 화합물 유도체 및 이의 약제학적 용도 |
| WO2026093435A1 (en) | 2024-10-31 | 2026-05-07 | Institut National de la Santé et de la Recherche Médicale | Use of jak inhibitors for enhancing the potency of immunotherapy in the treament of cancer |
Family Cites Families (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL83821A0 (en) | 1986-09-10 | 1988-02-29 | Sandoz Ag | Azaindole and indolizine derivatives,their production and pharmaceutical compositions containing them |
| US5304121A (en) | 1990-12-28 | 1994-04-19 | Boston Scientific Corporation | Drug delivery system making use of a hydrogel polymer coating |
| FR2687402B1 (fr) | 1992-02-14 | 1995-06-30 | Lipha | Nouveaux azaindoles, procedes de preparation et medicaments les contenant. |
| US5716981A (en) | 1993-07-19 | 1998-02-10 | Angiogenesis Technologies, Inc. | Anti-angiogenic compositions and methods of use |
| WO1995033748A1 (en) | 1994-06-09 | 1995-12-14 | Smithkline Beecham Corporation | Endothelin receptor antagonists |
| US6099562A (en) | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
| GB9721437D0 (en) | 1997-10-10 | 1997-12-10 | Glaxo Group Ltd | Heteroaromatic compounds and their use in medicine |
| FR2784375B1 (fr) * | 1998-10-12 | 2000-11-24 | Adir | Nouveaux derives cycliques a chaine cycloalkylenique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| US6265403B1 (en) | 1999-01-20 | 2001-07-24 | Merck & Co., Inc. | Angiogenesis inhibitors |
| US20030153560A1 (en) | 1999-04-23 | 2003-08-14 | Salituro Francesco G. | Inhibitors of c-Jun N-terminal kinases (JNK) |
| JP2003503456A (ja) | 1999-07-02 | 2003-01-28 | スチュアート エイ． リプトン | 神経傷害またはアポトーシスを軽減する方法 |
| ATE449764T1 (de) | 1999-12-28 | 2009-12-15 | Pharmacopeia Inc | Cytokine, insbesondere tnf-alpha, hemmer |
| HUP0301117A3 (en) | 2000-02-17 | 2004-01-28 | Amgen Inc Thousand Oaks | Imidazole derivatives kinase inhibitors, their use, process for their preparation and pharmaceutical compositions containing them |
| ES2266258T3 (es) | 2000-09-15 | 2007-03-01 | Vertex Pharmaceuticals Incorporated | Compuestos de pirazol utiles como inhibidores de proteina cinasas. |
| US20030165873A1 (en) * | 2001-03-02 | 2003-09-04 | Come Jon H. | Three hybrid assay system |
| US7081454B2 (en) | 2001-03-28 | 2006-07-25 | Bristol-Myers Squibb Co. | Tyrosine kinase inhibitors |
| DE60232510D1 (de) | 2001-06-15 | 2009-07-16 | Vertex Pharma | 5-(2-aminopyrimidin-4-yl)benzisoxazole als proteinkinasehemmer |
| GB0115109D0 (en) | 2001-06-21 | 2001-08-15 | Aventis Pharma Ltd | Chemical compounds |
| US20040236110A1 (en) | 2001-09-26 | 2004-11-25 | Ladouceur Gaetan H | Substituted 3-pyridyl indoles and indazoles as c17,20 lyase inhibitors |
| TW200306819A (en) | 2002-01-25 | 2003-12-01 | Vertex Pharma | Indazole compounds useful as protein kinase inhibitors |
| AU2003237121A1 (en) | 2002-04-26 | 2003-11-10 | Vertex Pharmaceuticals Incorporated | Pyrrole derivatives as inhibitors of erk2 and uses thereof |
| MXPA04010545A (es) | 2002-04-26 | 2005-01-25 | Pfizer Prod Inc | Inhibidores de metaloproteinasa de heteroariloxi-aril-espiero-pirimidina-2,4,6-triona n-sustituida. |
| KR20050004214A (ko) | 2002-05-31 | 2005-01-12 | 에자이 가부시키가이샤 | 피라졸 화합물 및 이것을 포함하여 이루어지는 의약 조성물 |
| UA78999C2 (en) | 2002-06-04 | 2007-05-10 | Wyeth Corp | 1-(aminoalkyl)-3-sulfonylazaindoles as ligands of 5-hydroxytryptamine-6 |
| ES2273043T3 (es) | 2002-08-02 | 2007-05-01 | Vertex Pharmaceuticals Incorporated | Composiciones de pirazol utiles como inhibidores de gsk-3. |
| SE0202463D0 (sv) | 2002-08-14 | 2002-08-14 | Astrazeneca Ab | Novel compounds |
| WO2004037814A1 (en) | 2002-10-25 | 2004-05-06 | Vertex Pharmaceuticals Incorporated | Indazolinone compositions useful as kinase inhibitors |
| EP1599475A2 (en) | 2003-03-06 | 2005-11-30 | Eisai Co., Ltd. | Jnk inhibitors |
| KR20050122210A (ko) | 2003-03-17 | 2005-12-28 | 다케다 샌디에고, 인코포레이티드 | 히스톤 탈아세틸화 효소 억제제 |
| GB0308466D0 (en) | 2003-04-11 | 2003-05-21 | Novartis Ag | Organic compounds |
| TWI339206B (en) | 2003-09-04 | 2011-03-21 | Vertex Pharma | Compositions useful as inhibitors of protein kinases |
| WO2005044181A2 (en) | 2003-09-09 | 2005-05-19 | Temple University-Of The Commonwealth System Of Higher Education | Protection of tissues and cells from cytotoxic effects of ionizing radiation by abl inhibitors |
| CN1897950A (zh) | 2003-10-14 | 2007-01-17 | 惠氏公司 | 稠合芳基和杂芳基衍生物及其使用方法 |
| PL1696920T3 (pl) | 2003-12-19 | 2015-03-31 | Plexxikon Inc | Związki i sposoby opracowywania modulatorów Ret |
| US7507826B2 (en) | 2004-03-30 | 2009-03-24 | Vertex Pharmaceuticals Incorporated | Azaindoles useful as inhibitors of JAK and other protein kinases |
| WO2005103050A2 (en) * | 2004-04-02 | 2005-11-03 | Vertex Pharmaceuticals Incorporated | Azaindoles useful as inhibitors of rock and other protein kinases |
| JP2008503473A (ja) | 2004-06-17 | 2008-02-07 | プレキシコン，インコーポレーテッド | Ｃ−ｋｉｔ活性を調節する化合物 |
| US20060122213A1 (en) * | 2004-06-30 | 2006-06-08 | Francoise Pierard | Azaindoles useful as inhibitors of protein kinases |
| EP2264033A1 (en) | 2004-07-27 | 2010-12-22 | SGX Pharmaceuticals, Inc. | 3,5-DIPHENYL-SUBSTITUTED PYRROLO[2,3b]PYRIDINES USEFUL AS KINASE INHIBITORS |
| GB0420719D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
| WO2006038001A1 (en) | 2004-10-06 | 2006-04-13 | Celltech R & D Limited | Aminopyrimidine derivatives as jnk inhibitors |
| US7855205B2 (en) | 2004-10-29 | 2010-12-21 | Janssen Pharmaceutica Nv | Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders |
| ZA200704888B (en) | 2004-11-22 | 2009-02-25 | Vertex Pharma | Pyrrolopyrazines and pyrazolopyrazines useful as inhibitors of protein kinases |
| AU2005316540A1 (en) | 2004-12-16 | 2006-06-22 | Vertex Pharmaceuticals Incorporated | Pyrid-2-ones useful as inhibitors of Tec family protein kinases for the treatment of inflammatory, proliferative and immunologically-mediated diseases |
| EP1844050B1 (en) * | 2005-02-03 | 2009-01-14 | Vertex Pharmaceuticals, Inc. | Pyrrolopyrimidines useful as inhibitors of protein kinase |
| BRPI0610828A2 (pt) | 2005-05-16 | 2010-07-27 | Irm Llc | compostos e composições como inibidores de proteìna quinase |
| KR20080016659A (ko) * | 2005-05-20 | 2008-02-21 | 버텍스 파마슈티칼스 인코포레이티드 | 단백질 키나제의 억제제로서 유용한 피롤로피리딘 |
| DK2395004T3 (en) | 2005-06-22 | 2016-03-21 | Plexxikon Inc | Pyrrolo [2,3-b] pyridine derivatives as protein kinase inhibitors |
| JP2009513571A (ja) * | 2005-09-30 | 2009-04-02 | バーテックス ファーマシューティカルズ インコーポレイテッド | ヤヌスキナーゼ阻害剤として有用なデアザプリン |
| TW201412738A (zh) * | 2006-01-17 | 2014-04-01 | Vertex Pharma | 適合作為傑納斯激酶（ｊａｎｕｓ ｋｉｎａｓｅ）抑制劑之氮雜吲哚 |
| CA2641254A1 (en) | 2006-02-14 | 2007-08-23 | Vertex Pharmaceuticals Incorporated | Pyrrolo(3,2-c) pyridines useful as inhibitors of protein kinases |
| CA2648250A1 (en) | 2006-04-05 | 2007-10-18 | Vertex Pharmaceuticals Incorporated | Deazapurines useful as inhibitors of janus kinases |
| CN101646671A (zh) | 2006-12-14 | 2010-02-10 | 弗特克斯药品有限公司 | 用作蛋白激酶抑制剂的化合物 |
| WO2008123796A2 (ru) | 2007-04-05 | 2008-10-16 | Alla Chem, Llc | Замещенные 2,3,4,5-tetpaгидpo-1h-пиpидo[4,3-b]иhдoлы, способ их получения и применения |
| US8173635B2 (en) | 2007-11-02 | 2012-05-08 | Vertex Pharmaceuticals Incorporated | Kinase inhibitors |
| JP2011513483A (ja) | 2008-03-10 | 2011-04-28 | バーテックス ファーマシューティカルズ インコーポレイテッド | タンパク質キナーゼの阻害剤として有用なピリミジンおよびピリジン |
| MX2014005565A (es) | 2011-11-07 | 2014-05-30 | Vertex Pharma | Metodos para tratar enfermedades inflamatorias y composiciones farmaceuticas utiles para los mismos. |
-
2007
- 2007-01-17 TW TW102147300A patent/TW201412738A/zh unknown
- 2007-01-17 CN CN2011103519191A patent/CN102532133A/zh active Pending
- 2007-01-17 EP EP07718337.4A patent/EP1973911B1/en active Active
- 2007-01-17 NZ NZ59296807A patent/NZ592968A/xx not_active IP Right Cessation
- 2007-01-17 JP JP2008551353A patent/JP5591471B2/ja not_active Expired - Fee Related
- 2007-01-17 AU AU2007207533A patent/AU2007207533B8/en not_active Ceased
- 2007-01-17 AR ARP070100199 patent/AR060316A1/es unknown
- 2007-01-17 CA CA 2636189 patent/CA2636189A1/en not_active Abandoned
- 2007-01-17 NZ NZ60168707A patent/NZ601687A/en not_active IP Right Cessation
- 2007-01-17 RU RU2008133613/04A patent/RU2453548C2/ru not_active IP Right Cessation
- 2007-01-17 US US11/654,375 patent/US7767816B2/en not_active Expired - Fee Related
- 2007-01-17 KR KR1020127014597A patent/KR101235103B1/ko not_active Expired - Fee Related
- 2007-01-17 BR BRPI0722364-1A patent/BRPI0722364A2/pt not_active IP Right Cessation
- 2007-01-17 EP EP20120176810 patent/EP2559694A3/en not_active Withdrawn
- 2007-01-17 NZ NZ569899A patent/NZ569899A/en not_active IP Right Cessation
- 2007-01-17 KR KR1020137005929A patent/KR20130041313A/ko not_active Withdrawn
- 2007-01-17 TW TW101137037A patent/TWI424999B/zh not_active IP Right Cessation
- 2007-01-17 BR BRPI0706537-0A patent/BRPI0706537A2/pt not_active IP Right Cessation
- 2007-01-17 UA UAA200810409A patent/UA95940C2/uk unknown
- 2007-01-17 KR KR1020087017472A patent/KR101409727B1/ko not_active Expired - Fee Related
- 2007-01-17 CN CN2011104033161A patent/CN102532134A/zh active Pending
- 2007-01-17 EP EP20120176813 patent/EP2537849A3/en not_active Withdrawn
- 2007-01-17 TW TW96101771A patent/TWI405761B/zh not_active IP Right Cessation
- 2007-01-17 WO PCT/US2007/001225 patent/WO2007084557A2/en not_active Ceased
- 2007-01-17 CN CN201510004860.7A patent/CN104650077A/zh active Pending
- 2007-01-17 TW TW101137542A patent/TWI423976B/zh not_active IP Right Cessation
-
2008
- 2008-06-03 IL IL191902A patent/IL191902A0/en unknown
- 2008-06-10 ZA ZA2008/05053A patent/ZA200805053B/en unknown
- 2008-07-21 CL CL2008002140A patent/CL2008002140A1/es unknown
- 2008-08-13 NO NO20083501A patent/NO20083501L/no not_active Application Discontinuation
-
2009
- 2009-04-30 HK HK15111605.7A patent/HK1210780A1/xx unknown
- 2009-06-12 ZA ZA2009/04147A patent/ZA200904147B/en unknown
-
2010
- 2010-05-07 US US12/775,885 patent/US8163917B2/en not_active Expired - Fee Related
-
2011
- 2011-12-14 RU RU2011151085/02A patent/RU2011151085A/ru not_active Application Discontinuation
-
2012
- 2012-03-01 US US13/409,702 patent/US8450489B2/en not_active Expired - Fee Related
- 2012-10-11 JP JP2012226367A patent/JP5728454B2/ja not_active Expired - Fee Related
- 2012-10-11 JP JP2012226368A patent/JP2013010793A/ja not_active Ceased
-
2013
- 2013-04-25 US US13/870,173 patent/US8822681B2/en not_active Expired - Fee Related
-
2014
- 2014-07-24 US US14/339,514 patent/US9120790B2/en not_active Expired - Fee Related
- 2014-08-20 JP JP2014167160A patent/JP2014210823A/ja active Pending
-
2015
- 2015-07-29 US US14/812,158 patent/US20160008359A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013010793A5 (enExample) | ||
| JP2016509047A5 (enExample) | ||
| JP2014511892A5 (enExample) | ||
| JP2017537940A5 (enExample) | ||
| PH12018550049A1 (en) | Protein kinase inhibitor, preparation method and medical use thereof | |
| RU2011124304A (ru) | Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе | |
| JP2018515495A5 (enExample) | ||
| JP2020169171A5 (enExample) | ||
| JP2015537020A5 (enExample) | ||
| JP2017511360A5 (enExample) | ||
| RU2019141734A (ru) | Терапевтические соединения и композиции и способы их применения | |
| EA201650029A1 (ru) | Пиразолопиридины и пиразолопиримидины | |
| EA201700077A1 (ru) | Соединения аминопиримидинила в качестве ингибиторов jak | |
| RU2011151085A (ru) | Азаиндолы, полезные в качестве ингибиторов янус-киназ | |
| RU2016134751A (ru) | Соединения | |
| RU2015107803A (ru) | Производные дигидроксипиримидинкарбоновой кислоты и их применение в лечении, облегчении или предотвращении вирусного заболевания | |
| JP2017524733A5 (enExample) | ||
| RU2017101829A (ru) | Пиразоловые соединения в качестве модуляторов fshr и пути их применения | |
| EA201370184A1 (ru) | Гетероарильные производные | |
| JP2015508092A5 (enExample) | ||
| JP2019510027A5 (enExample) | ||
| CY1124708T1 (el) | Φαρμακολογικως δραστικα αλικυκλικα υποκατεστημενα παραγωγα πυραζολο[1,5-a] πυριμιδινης | |
| JP2018513832A5 (enExample) | ||
| JP2019505529A5 (enExample) | ||
| JP2016529315A5 (enExample) |